GT201700280A - Formulación sólida oral que contiene irinotecán y método de preparación de la misma - Google Patents

Formulación sólida oral que contiene irinotecán y método de preparación de la misma

Info

Publication number
GT201700280A
GT201700280A GT201700280A GT201700280A GT201700280A GT 201700280 A GT201700280 A GT 201700280A GT 201700280 A GT201700280 A GT 201700280A GT 201700280 A GT201700280 A GT 201700280A GT 201700280 A GT201700280 A GT 201700280A
Authority
GT
Guatemala
Prior art keywords
irinotechan
preparing
formulation containing
solid oral
oral formulation
Prior art date
Application number
GT201700280A
Other languages
English (en)
Inventor
Caleb Hyung Min Park
Myeong Ki Jung
Jin Cheul Kim
Yong Il Kim
Jong Soo Woo
Jae Hyun Park
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of GT201700280A publication Critical patent/GT201700280A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

UNA FORMULACIÓN SÓLIDA ORAL INCLUYE IRINOTECÁN O UNA SAL ACEPTABLE FARMACÉUTICAMENTE DEL MISMO COMO UN INGREDIENTE ACTIVO Y UN AGENTE ACIDIFICANTE.
GT201700280A 2015-06-30 2017-12-21 Formulación sólida oral que contiene irinotecán y método de preparación de la misma GT201700280A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150093413A KR102293907B1 (ko) 2015-06-30 2015-06-30 이리노테칸 함유 경구용 고형제제 및 그 제조방법

Publications (1)

Publication Number Publication Date
GT201700280A true GT201700280A (es) 2019-10-10

Family

ID=57608859

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201700280A GT201700280A (es) 2015-06-30 2017-12-21 Formulación sólida oral que contiene irinotecán y método de preparación de la misma

Country Status (30)

Country Link
US (2) US11090299B2 (es)
EP (1) EP3300483B1 (es)
JP (2) JP6835746B2 (es)
KR (2) KR102293907B1 (es)
CN (1) CN107949375B (es)
AR (1) AR105203A1 (es)
AU (2) AU2016286804B2 (es)
BR (1) BR112017028468B1 (es)
CA (1) CA2988079C (es)
CL (1) CL2017003437A1 (es)
CO (1) CO2017013317A2 (es)
CR (1) CR20170604A (es)
DO (1) DOP2017000307A (es)
EC (1) ECSP17085443A (es)
ES (1) ES2930663T3 (es)
GT (1) GT201700280A (es)
IL (1) IL256278B (es)
JO (1) JO3683B1 (es)
MX (2) MX381735B (es)
MY (1) MY191297A (es)
PE (1) PE20181040A1 (es)
PH (1) PH12017502376B1 (es)
RU (1) RU2716595C2 (es)
SA (1) SA517390602B1 (es)
SG (1) SG10201913274VA (es)
SV (1) SV2017005603A (es)
TW (2) TW202137985A (es)
UY (1) UY36761A (es)
WO (1) WO2017003120A1 (es)
ZA (1) ZA201708429B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102293907B1 (ko) * 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
KR102185475B1 (ko) * 2019-06-20 2020-12-02 대화제약 주식회사 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물
KR102444073B1 (ko) * 2020-01-06 2022-09-16 (주)휴온스 안정성이 향상된 메틸에르고메트린말레산염 함유 약제학적 제제 및 이의 제조방법
PL3965741T3 (pl) * 2020-04-24 2023-10-02 Dr. Falk Pharma Gmbh Preparat ogólnoustrojowy pochodnej pirydynonowej do celiakii
KR20220006776A (ko) * 2020-07-09 2022-01-18 주식회사유한양행 다이아미노피리미딘 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물 및 이의 제조방법
EP4193987A4 (en) * 2020-08-06 2024-08-21 SK Biopharmaceuticals Co., Ltd. SOLID ORAL COMPOSITION COMPRISING A CARBAMATE COMPOUND AND PROCESS FOR ITS PREPARATION
TWI900672B (zh) 2020-10-07 2025-10-11 香港商希華醫藥有限公司 乙醯胺基－苯基四唑衍生物及其使用方法
DK4245298T3 (en) * 2020-12-18 2026-03-30 Daewoong Pharmaceutical Co Ltd Hidtil ukendt formulering til oral administration, som omfatter 1-(5-(2,4-difluorphenyl)-1-((3-fluorphenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamin
JP7853076B2 (ja) * 2021-05-11 2026-04-28 花王株式会社 顆粒の製造方法
WO2025064381A1 (en) * 2023-09-18 2025-03-27 Phathom Pharmaceuticals Inc. Method for preparing vonoprazan with reduced nitrosamine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
WO1999065493A1 (en) 1998-06-18 1999-12-23 The George Washington University Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
JP2002154963A (ja) * 2000-11-14 2002-05-28 Yakult Honsha Co Ltd 徐放性抗腫瘍剤
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
PL372318A1 (en) * 2002-03-01 2005-07-11 Pharmacia Italia S.P.A. Crystalline polymorphic form of irinotecan hydrochloride
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
JP4245384B2 (ja) * 2003-03-18 2009-03-25 株式会社ヤクルト本社 カンプトテシン類含有医薬組成物
US20050208146A1 (en) * 2003-10-30 2005-09-22 Pfizer Inc Novel dosage and administration method for oral camptosar
JP4829120B2 (ja) * 2004-10-01 2011-12-07 株式会社ヤクルト本社 イリノテカン酸付加塩
JP5228488B2 (ja) 2004-12-03 2013-07-03 メルク・シャープ・アンド・ドーム・コーポレーション 放出速度調節組成物を含有しているカルボキサミドｈｉｖインテグラーゼ阻害薬の医薬配合物
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
CN101283983A (zh) 2007-10-26 2008-10-15 南京长澳医药科技有限公司 一种稳定的喜树碱类药物脂质体组合物
US7880591B2 (en) 2008-02-01 2011-02-01 Apple Inc. Consumer abuse detection system and method
EP2153821A1 (en) * 2008-08-06 2010-02-17 BioAlliance Pharma Oral formulations of camptothecin derivatives
CN102617584B (zh) * 2012-03-14 2013-10-16 海南锦瑞制药股份有限公司 一种盐酸伊立替康化合物及其药物组合物
MA38121A1 (fr) * 2012-11-30 2016-10-31 Glaxosmithkline Llc Nouvelle composition pharmaceutique
JP6704345B2 (ja) * 2014-01-17 2020-06-03 オンコラル ファーマ エーピーエス 癌治療のためのイリノテカンの固体経口剤形
KR102293907B1 (ko) * 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법

Also Published As

Publication number Publication date
TWI750125B (zh) 2021-12-21
US11090299B2 (en) 2021-08-17
RU2017143849A3 (es) 2019-09-25
KR102293907B1 (ko) 2021-08-26
KR20210106946A (ko) 2021-08-31
ES2930663T3 (es) 2022-12-20
EP3300483A1 (en) 2018-04-04
ECSP17085443A (es) 2018-01-31
JP6835746B2 (ja) 2021-02-24
HK1246656A1 (zh) 2018-09-14
RU2716595C2 (ru) 2020-03-13
EP3300483B1 (en) 2022-11-09
EP3300483A4 (en) 2018-12-12
UY36761A (es) 2016-12-30
TW201713339A (zh) 2017-04-16
US20210330666A1 (en) 2021-10-28
PH12017502376A1 (en) 2018-06-25
JP2018519279A (ja) 2018-07-19
DOP2017000307A (es) 2018-03-15
MX381735B (es) 2025-03-13
BR112017028468B1 (pt) 2023-03-28
MX2021004439A (es) 2021-05-27
CR20170604A (es) 2018-04-27
CN107949375A (zh) 2018-04-20
WO2017003120A1 (en) 2017-01-05
AU2016286804A1 (en) 2017-11-30
CO2017013317A2 (es) 2018-03-28
KR102317664B1 (ko) 2021-10-26
JO3683B1 (ar) 2020-08-27
CN107949375B (zh) 2023-04-21
NZ737238A (en) 2024-03-22
SA517390602B1 (ar) 2022-11-09
KR20170003143A (ko) 2017-01-09
CL2017003437A1 (es) 2018-06-22
MY191297A (en) 2022-06-14
JP2021070705A (ja) 2021-05-06
PH12017502376B1 (en) 2018-06-25
PE20181040A1 (es) 2018-07-03
SG10201913274VA (en) 2020-03-30
AU2016286804B2 (en) 2021-03-25
IL256278A (en) 2018-02-28
BR112017028468A2 (pt) 2018-08-28
AR105203A1 (es) 2017-09-13
MX2017014994A (es) 2018-08-15
SV2017005603A (es) 2018-03-12
US20180153878A1 (en) 2018-06-07
CA2988079C (en) 2023-09-26
ZA201708429B (en) 2019-06-26
AU2021204259A1 (en) 2021-07-22
TW202137985A (zh) 2021-10-16
IL256278B (en) 2020-11-30
CA2988079A1 (en) 2017-01-05
RU2017143849A (ru) 2019-08-01

Similar Documents

Publication Publication Date Title
ECSP17085443A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma
CL2016002372A1 (es) Cenicriviroc para el tratamiento de la fibrosis.
IL264880A (en) Preparations for oral administration of active substances
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CO2017012645A2 (es) Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
MX376118B (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
GEP20237486B (en) Formulations of copanlisib
MX2017002737A (es) Farmaceutico que contiene inhibidor de transportador de fosfato dependiente de sodio.
MX390899B (es) Formulación de combinación de dosis fija, eflornitina y sulindaco.
MX383682B (es) Tratamiento para cancer de mama usando una combinación de una formulación liposomal catiónica de taxano, una formulación no liposomal de taxano y un agente activo adicional.
MX2017009863A (es) Agente preventivo y/o terapeutico de enfermedad inmune.
FR3025096B1 (fr) Composition gel/gel contenant un actif anti-transpirant
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
MX2018003381A (es) Profilactico o agente terapeutico para queratitis fungica.
MA39009A (fr) Compositions pharmaceutiques comprenant un agent actif
CO2017000354A2 (es) Desmopresina estabilizada
GT201700017A (es) Un agente de control de enfermedad posterior a cosecha y método de control de enfermedad posterior a cosecha
CL2018001236A1 (es) Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo.
CY1119636T1 (el) Φαρμακευτικο παρασκευασμα με βαση διοσμεκτιτη
CL2015001970A1 (es) Una formulación liquida para el cuidado oral que comprende una mezcla de terpenos como principio activo